Hepatocellular carcinoma
Conditions
Interventions
Sorafenib Tosilate (Nexavar)
Sponsors
Kanazawa Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. The patient's age is between 20 and 89 years old. 2. Unresectable HCC progression. 3. Child-Pugh class A or B. 4. PS 2 or less. 5. With or without treatment history of HCC. 6. Informed consent.
Exclusion criteria
Exclusion criteria: 1. Brain metastases. 2. Bleeding tendency. 3. Advanced ascites. 4. Hepatic encephalopathy (II or more). 5. Jaundice (serum bilirubin value of 3.0 mg/dL or more). 6. Serum AST or ALT value of more than 200 IU/L. 7. Hemoglobin blood value of less than 8.0 g/dL. 8. Neutrophil count of less than 1000 /microL. 9. Platelet count of less than 50000 /microL. 10. Difficult to control hypertension. 11. During dialysis. 12. Patients who are pregnant, suspected to be pregnant or breastfeeding. 13. Patient with drug allergy. 14. Patient uses other anticancer drugs. 15. Patients who are considered not to be eligible by the investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Compared with the previously reported the TTS and the OS. | — |
Countries
Japan
Contacts
Public ContactNobuyuki Toshikuni
Kanazawa Medical University Department of Gastroenterology
Outcome results
None listed